1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Parkinson’s
Disease Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Mechanism of Action (Dopamine Agonists,
Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT
Inhibitors, and Other Mechanisms of Action)
5.2.2. By Distribution Channel (Retail Pharmacies,
Hospital Pharmacies, Others)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
6.
Asia Pacific Parkinson’s
Disease Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Mechanism
of Action
6.2.2. By
Distribution Channel
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Parkinson’s Disease Drugs Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Mechanism of
Action
6.3.1.2.2.
By Distribution
Channel
6.3.2. India Parkinson’s Disease Drugs Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Mechanism of
Action
6.3.2.2.2.
By Distribution
Channel
6.3.3. Australia Parkinson’s Disease Drugs Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Mechanism of
Action
6.3.3.2.2.
By Distribution
Channel
6.3.4. Japan Parkinson’s Disease Drugs Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Mechanism of
Action
6.3.4.2.2.
By Distribution
Channel
6.3.5. South Korea Parkinson’s Disease Drugs Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Mechanism of
Action
6.3.5.2.2.
By Distribution
Channel
7.
Europe Parkinson’s
Disease Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1.
By Mechanism of Action
7.2.2.
By Distribution Channel
7.2.3. By
Country
7.3. Europe: Country Analysis
7.3.1. France Parkinson’s Disease Drugs Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Mechanism of
Action
7.3.1.2.2.
By Distribution
Channel
7.3.2. Germany Parkinson’s Disease Drugs Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Mechanism of
Action
7.3.2.2.2.
By Distribution
Channel
7.3.3. Spain Parkinson’s Disease Drugs Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Mechanism of
Action
7.3.3.2.2.
By Distribution
Channel
7.3.4. Italy Parkinson’s Disease Drugs Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Mechanism of
Action
7.3.4.2.2.
By Distribution
Channel
7.3.5. United Kingdom Parkinson’s Disease Drugs Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Mechanism of
Action
7.3.5.2.2.
By Distribution
Channel
8.
North America Parkinson’s
Disease Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1.
By Mechanism of Action
8.2.2.
By Distribution Channel
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Parkinson’s Disease Drugs Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Mechanism of
Action
8.3.1.2.2.
By Distribution
Channel
8.3.2. Mexico Parkinson’s Disease Drugs Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Mechanism of
Action
8.3.2.2.2.
By Distribution
Channel
8.3.3. Canada Parkinson’s Disease Drugs Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Mechanism of
Action
8.3.3.2.2.
By Distribution
Channel
9.
South America Parkinson’s
Disease Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1.
By Mechanism of
Action
9.2.2.
By Distribution
Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Parkinson’s Disease Drugs Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Mechanism of
Action
9.3.1.2.2.
By Distribution
Channel
9.3.2. Argentina Parkinson’s Disease Drugs Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Mechanism of
Action
9.3.2.2.2.
By Distribution
Channel
9.3.3. Colombia Parkinson’s Disease Drugs Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Mechanism of
Action
9.3.3.2.2.
By Distribution
Channel
10.
Middle East and Africa
Parkinson’s Disease Drugs Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Mechanism of Action
10.2.2.
By Distribution Channel
10.2.3. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Parkinson’s Disease Drugs Market Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Mechanism of
Action
10.3.1.2.2.
By Distribution
Channel
10.3.2. Saudi Arabia Parkinson’s Disease Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Mechanism of
Action
10.3.2.2.2.
By Distribution
Channel
10.3.3. UAE Parkinson’s Disease Drugs Market Outlook
10.3.3.1. Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Mechanism of
Action
10.3.3.2.2.
By Distribution
Channel
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers &
Acquisitions
13. Global Parkinson’s Disease Drugs Market: SWOT
Analysis
14.
Porter’s Five Forces
Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Product
15. PESTLE Analysis
16. Competitive Landscape
16.1.
Amneal
Pharmaceuticals LLC
16.1.1. Business
Overview
16.1.2. Company
Snapshot
16.1.3. Products
& Services
16.1.4. Financials
(In case of listed companies)
16.1.5. Recent
Developments
16.1.6. SWOT
Analysis
16.2.
AbbVie Inc.
16.2.1. Business
Overview
16.2.2. Company
Snapshot
16.2.3. Products
& Services
16.2.4. Financials
(In case of listed companies)
16.2.5. Recent
Developments
16.2.6. SWOT
Analysis
16.3.
Boehringer Ingelheim
International GmbH
16.3.1. Business
Overview
16.3.2. Company
Snapshot
16.3.3. Products
& Services
16.3.4. Financials
(In case of listed companies)
16.3.5. Recent
Developments
16.3.6. SWOT
Analysis
16.4.
GSK plc
16.4.1. Business
Overview
16.4.2. Company
Snapshot
16.4.3. Products
& Services
16.4.4. Financials
(In case of listed companies)
16.4.5. Recent
Developments
16.4.6. SWOT
Analysis
16.5.
Teva Pharmaceuticals
Industries Ltd
16.5.1. Business
Overview
16.5.2. Company
Snapshot
16.5.3. Products
& Services
16.5.4. Financials
(In case of listed companies)
16.5.5. Recent
Developments
16.5.6. SWOT
Analysis
16.6.
Pfizer Inc.
16.6.1. Business
Overview
16.6.2. Company
Snapshot
16.6.3. Products
& Services
16.6.4. Financials
(In case of listed companies)
16.6.5. Recent
Developments
16.6.6. SWOT
Analysis
16.7.
Novartis AG
16.7.1. Business
Overview
16.7.2. Company
Snapshot
16.7.3. Products
& Services
16.7.4. Financials
(In case of listed companies)
16.7.5. Recent
Developments
16.7.6. SWOT
Analysis
16.8.
F. Hoffmann-La Roche
Ltd
16.8.1. Business
Overview
16.8.2. Company
Snapshot
16.8.3. Products
& Services
16.8.4. Financials
(In case of listed companies)
16.8.5. Recent
Developments
16.8.6. SWOT
Analysis
16.9.
Kissei
Pharmaceutical Co., Ltd.
16.9.1. Business
Overview
16.9.2. Company
Snapshot
16.9.3. Products
& Services
16.9.4. Financials
(In case of listed companies)
16.9.5. Recent
Developments
16.9.6. SWOT
Analysis
16.10.AstraZeneca Plc
16.10.1.
Business Overview
16.10.2.
Company Snapshot
16.10.3.
Products & Services
16.10.4.
Financials (In case of listed companies)
16.10.5.
Recent Developments
16.10.6.
SWOT Analysis
16.11.Prevail Therapeutics Inc.
16.11.1.
Business Overview
16.11.2.
Company Snapshot
16.11.3.
Products & Services
16.11.4.
Financials (In case of listed companies)
16.11.5.
Recent Developments
16.11.6.
SWOT Analysis
16.12.Newron Pharmaceuticals SPA
16.12.1.
Business Overview
16.12.2.
Company Snapshot
16.12.3.
Products & Services
16.12.4.
Financials (In case of listed companies)
16.12.5.
Recent Developments
16.12.6.
SWOT Analysis
17.
Strategic Recommendations
18. About Us & Disclaimer